Form D · Biotechnology
Kadmon I LLC
New York, NY · CIK 0001497178
Offering snapshot reported Jul 22, 2010 · SEC filing
- Reported sold
- $10.8M Offering amount: $50M
- Investors reported
- 26 Form D · investor count
- Minimum accepted
- $100K Reported outside-investor minimum
- First sale
- Jul 9, 2010 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 22, 2010 | Initial | $10,835,000 | No comparison | 26 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $547K
- Finders' fees
- $0
- Form D file number
- 021-145358
Issuer may, in it's discretion, increase the offering size to up to $175 million.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| John Thomas Financial | 40982 |
Source: Form D, filed Jul 22, 2010. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven N Gordon | Executive |
| Samuel D Waksal | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
400 Madison Ave
New York, NY, 10017
New York, NY, 10017